Download oncology development pipeline

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
ONCOLOGY DEVELOPMENT PIPELINE
PROGRAM
DESCRIPTION
DEVELOPMENT RIGHTS
DISEASE(S) UNDER INVESTIGATION
CD30 Antibody Drug Conjugate
Global†‡
Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma,
Mature T-Cell Lymphoma
VECTIBIX®
Anti-EGFR Antibody
Japan Only
Colorectal Cancer
LEUPLIN®
LH-RH Agonist
Japan Only
Prostate Cancer, Breast Cancer, new formulation
NINLARO®
Proteasome Inhibitor
Global
Multiple Myeloma, Amyloidosis
TAK-228
TORC1/TORC2 Inhibitor
Global
Breast Cancer, Renal Cell Carcinoma, Endometrial Cancer
PEVONEDISTAT
Nedd8-Activating Enzyme Inhibitor
Global
High-Risk Myelodysplastic Syndrome,
Acute Myelogenous Leukemia
TAK-659
SYK/FLT-3 Kinase Inhibitor
Global
Lymphoma, Acute Myelogenous Leukemia
Solid Tumors
TAK-117
PI3K Alpha Inhibitor
Global
Non-Small Cell Lung Cancer
TAK-580
Pan-Raf Kinase Inhibitor
Global
Solid Tumors
TAK-243
UAE Inhibitor
Global
Solid Tumors
TAK-931
CDC7 Inhibitor
Global
Solid Tumors
XMT-1522
HER2 Dolaflexin ADC
Ex-US, Ex-Canada*
Breast Cancer
ADCETRIS®
(brentuximab vedotin)
†‡
(panitumumab)†
(Leuprorelin acetate)
(ixazomib)
‡ADCETRIS® is co-developed by Takeda and Seattle Genetics, Inc.
†In-Licensed
*
XMT-1522 is co-developed by Takeda and Mersana Therapeutics
All registered trademarks are the sole property of their respective owners.
Last updated 10/20/2016
OMS/ONC/15/0015(4)
PHASE 1
PHASE 2
PHASE 3
Related documents